trastuzumab deruxtecan

01/01/2022 - "In patients with metastatic HER2+ breast cancer, trastuzumab deruxtecan has recently shown dramatically improved efficacy over T-DM1. "
11/30/2023 - "Despite the higher efficacy of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer, our findings raise concern regarding its value at current prices."
01/01/2023 - "In conclusion, trastuzumab deruxtecan is a valuable new treatment option for HER2-positive breast cancer, having been shown to be effective with a generally manageable safety and tolerability profile in adults with unresectable or metastatic disease who have received one or more prior anti-HER2-based regimens. "
11/01/2021 - "Fam-trastuzumab deruxtecan-nxki is an effective treatment for HER2-positive breast cancer in the metastatic setting, but randomized controlled trials are needed."
12/01/2023 - "Trastuzumab deruxtecan was not a cost-effective treatment option for patients with HER2-positive metastatic breast cancer in China. "

07/01/2016 - "These results indicated that DS-8201a has a potent bystander effect due to a highly membrane-permeable payload and is beneficial in treating tumors with HER2 heterogeneity that are unresponsive to T-DM1. "
01/01/2023 - "Based on the available evidence, trastuzumab deruxtecan appears to be an effective and safe treatment option for HER2-positive solid tumors. "
10/15/2017 - "Owing to these unique characteristics and unlike T-DM1, DS-8201a is effective against cancers with low-HER2 expression. "
10/23/2023 - "Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial."
01/01/2023 - "The results of these trials will enhance our understanding of trastuzumab deruxtecan and potentially expand its applications, bringing hope to more patients with solid tumors."

04/17/2022 - "Trastuzumab deruxtecan (T-DXd) has shown promising efficacy against HER2-positive advanced gastric cancer (AGC). "
10/15/2017 - "In conclusion, the efficacy of DS-8201a as a treatment for patients with T-DM1-resistant breast or gastric cancer merits investigation."
11/14/2023 - "Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study."
11/02/2023 - "Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer: a plain language summary of the DESTINY-Gastric01 study."
01/01/2019 - "Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study."

11/01/2023 - "In the DESTINY-Gastric02 trial, trastuzumab deruxtecan was able to induce confirmed (4 weeks after the initial response) complete or partial responses in adults from the USA or Europe with advanced gastric or GOJ adenocarcinoma. "
11/01/2023 - "In the phase II DESTINY-Gastric02 trial, trastuzumab deruxtecan was able to induce durable response in adults from the USA or Europe with unresectable or metastatic HER2-positive gastric or GOJ adenocarcinoma. "
11/01/2023 - "Current evidence indicates that trastuzumab deruxtecan is an effective treatment option, and is generally tolerable, in previously treated adults with advanced HER2+ gastric or GOJ adenocarcinoma."
11/01/2023 - "Current evidence indicates that trastuzumab deruxtecan is an effective treatment option, and is generally tolerable, in previously treated adults with advanced HER2-positive gastric or GOJ adenocarcinoma. "
11/01/2023 - "Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma."

05/08/2023 - "DESTINY-Lung01 and DESTINY-Lung02 demonstrated the efficacy of trastuzumab deruxtecan in the subsequent line setting in patients with unresectable or metastatic HER2-mutated non-small-cell lung cancer (NSCLC). "
01/01/2021 - "Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report."
11/01/2023 - "Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial."
11/01/2023 - "Optimizing Dosing of Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer: A Reminder That More Is Not Always Better."
08/25/2023 - "Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report."